Breaking News
November 18, 2018 - Consensus Statement Issued on Management of Foot, Ankle Gout
November 18, 2018 - Fine particle air pollution is a public health emergency hiding in plain sight
November 18, 2018 - In-hospital mortality higher among patients with drug-resistant infections
November 17, 2018 - Research shines new, explanatory light on link between obesity and cancer
November 17, 2018 - FIND explores new diagnostic assays for confirmatory HCV diagnosis in community settings
November 17, 2018 - Tracking Preemies’ Head Size May Yield IQ Clues
November 17, 2018 - Scientists call for unified standards in 3-D genome and epigenetic data
November 17, 2018 - Lab Innovations 2018 has beaten all records by attracting 3,113 attendees
November 17, 2018 - Sexuality education before age 18 may reduce risk of sexual assault in college
November 17, 2018 - Lab Innovations 2018 confirmed as a major hit with visitors, exhibitors and speakers
November 17, 2018 - Largest parasitic worm genetic study hatches novel treatment possibilities
November 17, 2018 - Static and dynamic physical activities offer varying protection against heart disease
November 17, 2018 - Obesity significantly increases risk of Type 2 diabetes and coronary artery disease
November 17, 2018 - People with rare cancers can benefit from genomic profiling, shows research
November 17, 2018 - NIH awards over $1.8 million to husband-and-wife doctors to test new breast cancer approach
November 17, 2018 - Four-in-one antibody used to fight flu shows promise in mice
November 17, 2018 - New approach allows pathogens to be starved by blocking important enzymes
November 17, 2018 - Higher body mass index could cause depression even without health problems
November 17, 2018 - Protein which plays role in sensing cell damage serves as new target to treat pulmonary hypertension
November 17, 2018 - FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
November 17, 2018 - ID specialist input improves outcomes for outpatient parenteral antimicrobial therapy
November 17, 2018 - UT Southwestern scientists selected to receive 2019 Edith and Peter O’Donnell Awards
November 17, 2018 - New clinical algorithm to help individuals manage type 2 diabetes when fasting during Ramadan
November 17, 2018 - Researchers identify LZTR1 as evolutionarily conserved component of RAS pathway
November 17, 2018 - Heart Disease Leading Cause of Death in Low-Income Counties
November 17, 2018 - Estrogen Levels Test: MedlinePlus Lab Test Information
November 17, 2018 - Research reveals link between immunity, diabetes
November 17, 2018 - Research shows how to achieve improved smoking cessation outcomes within California’s Medicaid population
November 17, 2018 - New study finds less understanding and implementation of patient engagement
November 17, 2018 - New shoe insole technology could help diabetic ulcers heal better while walking
November 17, 2018 - New method to extend cell division and immortalization of avian-derived cells
November 17, 2018 - Australian Academy of Science urges parents to vaccinate children against meningococcal disease
November 17, 2018 - Hot water treatment may help improve inflammation and metabolism in sedentary people
November 17, 2018 - Researchers produce 3D chemical maps of small biological samples
November 17, 2018 - Must Blood Pressure Rise Wth Age? Remote Tribes Hold Clues
November 17, 2018 - Noonan Syndrome
November 17, 2018 - Interventions to delay and prevent type 2 diabetes are underused, researchers say
November 17, 2018 - Hackathon prize winner seeks to remotely monitor patient skin conditions
November 17, 2018 - Research team identifies Ashkenazi Jewish founder mutation for Leigh syndrome
November 17, 2018 - Gene editing could be used to halt kidney disease in patients with Joubert syndrome
November 17, 2018 - Study uncovers link between gut disruption and aging
November 17, 2018 - Teens more likely to pick up smoking after exposure from friends and family
November 17, 2018 - Nicoya designate the Institute for Stem Cell Biology and Regenerative Medicine as the OpenSPR Centre of Excellence
November 17, 2018 - new horizon in dental, oral and craniofacial research
November 17, 2018 - How does poor air quality affect your health?
November 17, 2018 - New device can regulate children’s blood glucose more like natural pancreas
November 17, 2018 - Game-Changers in Western Blotting and Protein Analysis
November 17, 2018 - FDA announces new actions to limit sale of e-cigarettes to youth
November 17, 2018 - Warmer winter temperatures related to higher crime rates
November 17, 2018 - MCO places increasing emphasis on helping people find and access healthy food
November 17, 2018 - Group of students aim to improve malaria diagnosis using old smartphones
November 17, 2018 - Transplantation of feces may protect preterm children from deadly bowel disease
November 17, 2018 - Researchers explore whether low-gluten diets can be recommended for people without allergies
November 17, 2018 - New and better marker for assessing patients after cardiac arrest
November 17, 2018 - For 7-year-old with failing bone marrow, a life-saving transplant | News Center
November 17, 2018 - New first-line treatment for peripheral T-cell lymphoma approved by FDA
November 17, 2018 - Artificial intelligence could be valuable tool to help young victims disclose traumatic testimony
November 17, 2018 - Breakthrough in the treatment of Restless Legs Syndrome
November 16, 2018 - FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
November 16, 2018 - Eagle Books | Native Diabetes Wellness Program
November 16, 2018 - Patients with common heart failure more likely to have lethal heart rhythms
November 16, 2018 - How AI could help veterinarians code their notes | News Center
November 16, 2018 - Bias-based bullying does more harm to students than generalized bullying
November 16, 2018 - Researchers find first direct evidence that cerebellum plays role in cognitive functions
November 16, 2018 - Non-coding genetic variant plays key role in endothelial function and disease incidence
November 16, 2018 - EMA recommends first all-oral treatment to tackle deadly sleeping sickness
November 16, 2018 - Drug used to treat dizziness may slow down growth of triple-negative breast cancer
November 16, 2018 - AHA: Icosapent Ethyl Cuts CV Risk From Elevated Triglycerides
November 16, 2018 - ‘Orphan’ RNAs make cancer deadlier, but potentially easier to diagnose
November 16, 2018 - Air Cube touches down at hospital | News Center
November 16, 2018 - CRISPR-based tool shown to enhance cell-based immunotherapy
November 16, 2018 - Mechanisms that govern HIV latency differ in the gut and blood, finds study
November 16, 2018 - Researchers unravel mystery of NPM1 protein in acute myeloid leukemia
November 16, 2018 - High school students less likely to select milk, fruit for lunch when fruit juice is available
November 16, 2018 - Football coaches with great emotional competence are more successful
November 16, 2018 - Researchers awarded $10 million grant to address root causes of asthma in Puerto Rico
November 16, 2018 - Personalized scheduling of radiotherapy using genetic data could reduce side effects
November 16, 2018 - American Cancer Society study links social isolation to higher mortality risk
November 16, 2018 - Health Tip: Manage Morning Sickness
November 16, 2018 - Long term exposure to road traffic noise linked with greater obesity risk
Researchers identify new anti-inflammatory drug target

Researchers identify new anti-inflammatory drug target

image_pdfDownload PDFimage_print

A collaborative study conducted by the Division of Hemostasis and Thrombosis at Beth Israel Deaconess Medical Center (BIDMC) and the Wyss Institute at Harvard University suggests that parmodulins may provide anti-inflammatory and anti-thrombotic protection to endothelial cells, without interfering with blood clotting.

Credit: Illustration Forest/Shutterstock.com

This discovery makes parmodulins an attractive new drug candidate.

Inflammation is one of the most vital and troublesome processes in the human body. Although inflammatory responses are critical for engaging the immune system to overcome disease and injury, they can also lead to a rise in the production of thrombin, which may in turn cause harmful blood clots and other conditions.

Activated protein C (APC) is a natural anticoagulant protein used for treating severe blood infections and wounds. Although APC possesses anti-inflammatory and other protective effects, its use is limited as its inhibition of thrombin affects the blood’s ability to clot, and increases bleeding risk.

Paramodulins are synthetic activated protein C (APC)-mimicking small molecules.

In the present study, the researchers performed a mini preclinical trial of parmodulins’ effect on the endothelium. They identified the pathway through which parmodulins function, and demonstrated that they help protect endothelial cells from inflammatory damage.

The transmembrane protein protease-activated receptor 1 (PAR1) is the target protein on which both APC and parmodulins act. PAR1 makes mechanistic analysis difficult as it is present on both endothelial cells that line blood vessels as well as on platelets that circulate through the blood and promote clotting.

PAR1 was earlier identified as a receptor for thrombin; an important factor in the inflammatory process. Yet, when it is activated on the endothelium by APC, it triggers anti-apoptotic, anti-inflammatory, and barrier-fortifying pathways that help in protecting cells from the adverse impacts of inflammation.

Apart from activating PAR1, APC also inhibits the generation of thrombin independently, which is a vital element of healthy blood clotting. However, excessive inhibition of thrombin results in uncontrolled bleeding.

As the researchers knew that parmodulins bind to PAR1, they aimed to find a way to activate endothelial PAR1 and decrease thrombic responses without thinning the blood, and thereby provide a better substitute for APC.

Human endothelial cells were incubated with parmodulin 2 in vitro for 4 hours in order to examine the activity of parmodulins on the endothelium. It was then exposed to lipopolysaccharide (LPS); the thrombin-inducing inflammatory agent, or tumor necrosis factor-α (TNF-α).

In comparison with non-parmodulin-exposed cells, the ability of both the agents to generate thrombin was decreased by more than 50% in the parmodulin-exposed cells. However, the activity of factor V or factor X, proteins that function in blood coagulation was not inhibited by parmodulin.

We were intrigued by the notion that parmodulin 2 inhibited LPS- and TNF-mediated prothrombotic effects on the endothelial surface without impairing blood clotting.”

Dr. Karen De Ceunynck, postdoctoral research fellow at BIDMC and the first author of the paper

A blood-vessel-on-a-chip developed at Wyss institute that consisted of microfluidic channels embedded in a clear polymer chip, coated with collagen, and lined by human endothelial cells was used to validate this theory.

To simulate the flow conditions within human blood vessels, whole blood was perfused through the chip along with  various pro- and anti-inflammatory compounds.

The researchers found that during a typical inflammatory response, platelets exposed to TNF-α concentrated on the endothelium. However, when exposed to paramodulin 2 prior to TNF-α, was inhibited and the endothelium resumed its normal function.

Thus, the results suggested that parmodulin exposure blocks the thrombotic response of endothelium to inflammatory response, without affecting blood coagulation in humans.

A set of in vitro tests performed by Dr. Christian Peters, at BIDMC, confirmed that activation of PAR1 by parmodulin 2 induces cytoprotective responses in endothelial cells by inhibiting apoptosis, normally induced by thrombin, TNF-α, and the apoptotic alkaloid staurosporine.

This occurs via a signaling pathway that starts with the binding of parmodulin 2 to a specific site on the cytoplasmic side of PAR1.

Dr. Peters commented: “We observed that the cytoprotective response induced by parmodulin 2 happened very quickly, and confirmed its rapid onset in time course and gene expression assays.”

In vivo studies in mice indicated that parmodulin 2 decreases the binding of white blood cells to blood vessels and impairs platelet and fibrin accumulation at injury sites during the inflammatory response.

This observation confirmed the anti-coagulant and anti-thrombotic activity of parmodulin 2 seen in vitro.

Parmodulins don’t interact with many of APC’s other binding partners. This property makes it much more targeted to PAR1 and reduces other side effects.

According to Professor Rob Flaumenhaft, M.D., Ph.D., Professor of Medicine at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis at BIDMC, and corresponding author of the paper, the discovery of an anti-inflammatory molecule that prevents endothelial thrombosis and also preserves normal blood coagulation is a major step forward in the treatment of inflammatory diseases.

Professor Flaumenhaft added, “Nearly all other pharmaceuticals that target G-protein coupled receptors like PAR1 bind to the exterior of the receptor. Parmodulin 2 represents a paradigm shift for compounds targeting GPCRs because it acts on internal domains. We are excited to see if we can advance it to clinical trials”

This work provides another example of how organ-on-a-chip technology can enable faster and safer development and evaluation of drugs that could help patients around the world.”

Donald Ingber, M.D., Ph.D., co-author and Wyss Institute Founding Director

Tagged with:

About author

Related Articles